Williams, Juliet A

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine

Cancer Cells and MetastasisCancer Genomics and Diagnostics

Cited by 1,393

The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival

Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and Cancer

Cited by 347

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 167

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife

Lung Cancer Treatments and MutationsGenomics, phytochemicals, and oxidative stress

Cited by 160

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Hao, H.-X., Wang, H., Liu, C., Kovats, S., Velazquez, R., Lu, H., Pant, B., Shirley, M., Meyer, M. J., Pu, M., et al. (2019) · Molecular Cancer Therapeutics

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 53

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

Wang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., et al. (2017) · eLife

Neuroblastoma Research and TreatmentsLung Cancer Treatments and Mutations

Cited by 45

CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers

Kwiatkowski, N., Liang, T., Sha, Z., Collier, P. N., Yang, A., Sathappa, M., Paul, A., Su, L., Zheng, X., Aversa, R., et al. (2025) · Cell Chemical Biology

Protein Degradation and InhibitorsAdvanced Breast Cancer Therapies

Cited by 23